D3 Bio
D3 Bio is a clinical-stage biotechnology company focused on discovering, developing, and registering new oncology and immunology medicines. They leverage clinical insight and biomarker strategies to create novel therapies for patients. Their lead asset, D3S-001, is a next-generation KRAS G12C inhibitor currently in Phase II development.
Funding Round: Series A+
Funding Amount: $62M
Date: 08-Apr-2024
Investors: Medicxi, Matrix Partners China, WuXi AppTec's Corporate Venture Fund
Markets: Biotechnology, Oncology, Immunology, Life Science, Pharmaceutical
HQ: Wuxi, Jiangsu, China
Founded: 2018
Website: https://www.d3bio.com/
LinkedIn: https://www.linkedin.com/company/d3bio
Crunchbase: https://www.crunchbase.com/organization/d3-bio
Leave a Comment
Comments
No comments yet.